HBK Sorce Advisory’s Calliditas Therapeutics AB American Depositary Shares CALT Stock Holding History

HBK Sorce Advisory’s Portfolio CALT Stock Details CALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-90,000	Closed	-$104K	–	848
2022 Q4	$104K	Buy	90,000 +45,000	+100%	+$726K	﹤0.01%	690
2022 Q3	$50K	Buy	+45,000	New	+$784K	﹤0.01%	517

Other funds holding CALT

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

IIM

Ironwood Investment Management Boston, Massachusetts $240M AUM 45.82% 1-Year Est. Return

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HBK Sorce Advisory's CALT Position: Q1 2023 in Review

HBK Sorce Advisory sold out of Calliditas Therapeutics AB American Depositary Shares (CALT) in Q1 2023, closing a stake of 90,000 shares — an estimated $104K sold.

HBK Sorce Advisory first reported a position in CALT in Q3 2022 and held it in 2 quarters. The position peaked at $104K in Q4 2022. 14 funds tracked by Wall St. Rank hold CALT as of Q1 2023.

HBK Sorce Advisory reported no remaining Calliditas Therapeutics AB American Depositary Shares position as of Q1 2023 after selling out during the quarter.
HBK Sorce Advisory sold 90,000 Calliditas Therapeutics AB American Depositary Shares shares in Q1 2023, an estimated $104K.
HBK Sorce Advisory first reported a position in Calliditas Therapeutics AB American Depositary Shares in Q3 2022 and held it in 2 quarters.
HBK Sorce Advisory's Calliditas Therapeutics AB American Depositary Shares position peaked at $104K in Q4 2022.
14 funds tracked by Wall St. Rank held Calliditas Therapeutics AB American Depositary Shares as of Q1 2023.

Based on HBK Sorce Advisory's 13F filing for Q1 2023, filed 15 May 2023.